Another study demonstrated that agrin protein derived from extracellular vesicles of pancreatic cancer stem cells promotes YAP activation via LRP-4, aiding non-stem cancer cells in adaptation and proliferation, while anti-agrin therapies offer targeted treatment for patients with pancreatic ductal adenocarcinoma [48]. The gene discussed is LRP4; the disease is familial pancreatic carcinoma.